CEO Total Pay
$10.1M
FY2023 Summary Compensation, above median
RVNC FY2023 SEC EDGAR DEF 14A
Revance Therapeutics, Inc. CEO pay ratio
The CEO earned $10.1M in FY2023 against median worker pay of $238,081 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2024-03-21
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2023
Data updated August 2026
Subscribe to Revance Therapeutics, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
42:1
Below Average (Scale: 0–1000:1)
CEO pay
$10.1M
Median worker
$238,081
Latest filing FY2023. This company's newest DEF 14A on file is for FY2023, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Revance Therapeutics, Inc. reported a 42:1 CEO-to-worker pay ratio in FY2023 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 42:1
- FY2023 disclosed
- CEO total
- $10.1M
- Summary Compensation Table total
- Median worker
- $238,081
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2023
A component-level pay breakdown is not reported in Revance Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Revance Therapeutics, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2023. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 42:1
- FY2023
- vs prior FY
- +12:1
- from FY2022 30:1
- CEO $ YoY
- +52%
- $10.1M latest
- Filings shown
- 3
- FY2021–2023
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $7.1M | - | $248,326 | 29:1 | - |
| 2022 | $6.6M | -7% | $222,907 | 30:1 | +1:1 |
| 2023 | $10.1M | +52% | $238,081 | 42:1 | +12:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1479290, FY2021–2023. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
42:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$10.1M
Companies in Industry
168
vs. Industry Median
Below
Revance Therapeutics, Inc.: MODEST · HEAVY pay ratio
Revance Therapeutics, Inc. disclosed 42:1 CEO-to-worker pay and $10.1M CEO total in FY2023. the CEO earned 42× the median employee ($238,081) in FY2023.
Median employee $238,081 (ELITE-MED); MODEST · HEAVY stamps put about 42 median-wage years per CEO year.
Pay Ratio
42:1
Below typical
What FY2023 shows for Revance Therapeutics, Inc.
Revance Therapeutics, Inc. disclosed 42:1 CEO-to-worker pay and $10.1M CEO total in FY2023. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Revance Therapeutics, Inc.'s $10.1M CEO total is above the $7.9M industry median CEO pay.
Revance Therapeutics, Inc. stamps MODEST · HEAVY · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2023
- Total Compensation
- $10.1M
- Median Employee Pay
- $238,081
- Pay Ratio
- 42:1
- Filing Date
- 2024-03-21
Company Info
- Ticker
- RVNC
- CIK
- 1479290
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1479290, FY2023. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Revance Therapeutics, Inc. disclosed 42:1 CEO-to-worker pay and $10.1M CEO total in FY2023.
Read with Revance Therapeutics, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.
Xenon Pharmaceuticals Inc. · HEAVY
ABS(ceo_total_comp) peer at $10.1M (Δ $4K heavier vs Revance Therapeutics, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
EDGEWELL PERSONAL CARE Co · HEAVY
ABS(ceo_total_comp) peer at $10.1M (Δ $8K lighter vs Revance Therapeutics, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
YETI Holdings, Inc. · HEAVY
ABS(ceo_total_comp) peer at $10.1M (Δ $8K heavier vs Revance Therapeutics, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Carters Inc · HEAVY
ABS(ceo_total_comp) peer at $10.1M (Δ $13K heavier vs Revance Therapeutics, Inc.); EXTREME · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Revance Therapeutics, Inc. stamps MODEST · HEAVY · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MODEST
See where MODEST · HEAVY packages sit on the national leaderboard after reading Revance Therapeutics, Inc..
Ratio primer · MODEST
Revance Therapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Revance Therapeutics, Inc. (CIK 1479290), FY2023. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.